Becton Dickinson and (NYSE:BDX) had its price objective reduced by KeyCorp from $262.00 to $256.00 in a report issued on Wednesday morning, The Fly reports. KeyCorp currently has an overweight rating on the medical instruments supplier’s stock. KeyCorp also issued estimates for Becton Dickinson and’s Q1 2020 earnings at $2.60 EPS, Q2 2020 earnings at $3.01 EPS, Q3 2020 earnings at $3.25 EPS, Q4 2020 earnings at $3.66 EPS, FY2020 earnings at $12.57 EPS and FY2021 earnings at $14.19 EPS.
A number of other equities analysts also recently commented on the company. Piper Jaffray Companies decreased their price target on Becton Dickinson and from $267.00 to $266.00 and set an overweight rating for the company in a research note on Tuesday, August 6th. Wells Fargo & Co decreased their price target on Becton Dickinson and from $290.00 to $285.00 and set an outperform rating for the company in a research note on Wednesday, November 6th. Morgan Stanley lifted their price target on Becton Dickinson and from $250.00 to $261.00 and gave the stock an equal weight rating in a research note on Tuesday, July 16th. Finally, ValuEngine cut shares of Becton Dickinson and from a buy rating to a hold rating in a report on Thursday, August 1st. Five investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of Buy and an average target price of $265.55.
NYSE:BDX traded down $0.50 during mid-day trading on Wednesday, reaching $248.30. The stock had a trading volume of 977,298 shares, compared to its average volume of 1,363,446. The company has a market capitalization of $66.68 billion, a price-to-earnings ratio of 21.26, a price-to-earnings-growth ratio of 1.74 and a beta of 1.09. Becton Dickinson and has a 1-year low of $208.62 and a 1-year high of $264.74. The stock’s 50 day simple moving average is $251.03 and its two-hundred day simple moving average is $247.32. The company has a debt-to-equity ratio of 0.85, a current ratio of 1.19 and a quick ratio of 0.73.
Becton Dickinson and (NYSE:BDX) last posted its quarterly earnings results on Tuesday, November 5th. The medical instruments supplier reported $3.31 EPS for the quarter, topping the Zacks’ consensus estimate of $3.30 by $0.01. The business had revenue of $4.58 billion during the quarter, compared to the consensus estimate of $4.57 billion. Becton Dickinson and had a return on equity of 15.51% and a net margin of 6.84%. The company’s revenue for the quarter was up 4.1% compared to the same quarter last year. During the same period last year, the firm earned $2.93 earnings per share. Sell-side analysts anticipate that Becton Dickinson and will post 12.57 EPS for the current fiscal year.
In other Becton Dickinson and news, EVP Alexandre Conroy sold 9,829 shares of the firm’s stock in a transaction dated Thursday, August 29th. The shares were sold at an average price of $255.06, for a total value of $2,506,984.74. Following the transaction, the executive vice president now owns 16,535 shares of the company’s stock, valued at $4,217,417.10. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Charles R. Bodner sold 1,514 shares of the firm’s stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $260.08, for a total transaction of $393,761.12. Following the completion of the transaction, the senior vice president now directly owns 5,180 shares in the company, valued at approximately $1,347,214.40. The disclosure for this sale can be found here. Insiders sold 32,174 shares of company stock worth $8,354,013 in the last three months. 0.12% of the stock is currently owned by corporate insiders.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. TRUE Private Wealth Advisors bought a new stake in shares of Becton Dickinson and during the second quarter valued at approximately $25,000. Allworth Financial LP raised its holdings in shares of Becton Dickinson and by 386.4% during the third quarter. Allworth Financial LP now owns 107 shares of the medical instruments supplier’s stock valued at $27,000 after buying an additional 85 shares during the last quarter. Northwest Investment Counselors LLC bought a new stake in shares of Becton Dickinson and during the third quarter valued at approximately $27,000. Hexavest Inc. bought a new stake in shares of Becton Dickinson and during the second quarter valued at approximately $28,000. Finally, Lipe & Dalton bought a new stake in shares of Becton Dickinson and during the second quarter valued at approximately $28,000. 84.52% of the stock is currently owned by institutional investors.
About Becton Dickinson and
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Featured Story: What causes a yield curve to invert?
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.